Is a randomized controlled trial of waterbirth possible? An Australian feasibility study.

Birth

Molly Wardaguga Research Centre, College of Nursing and Midwifery, Charles Darwin University, Brisbane, Queensland, Australia.

Published: December 2022

AI Article Synopsis

  • The safety of waterbirth is debated due to insufficient evidence from randomized trials, prompting a study to evaluate its feasibility.
  • In a cohort study at an Australian maternity hospital, 1,260 women were recruited, with 15% open to participating in future randomizations; comparisons were made between those intending to have a waterbirth and those opting for traditional birth.
  • Results showed waterbirth participants had fewer medical interventions but no significant difference in serious neonatal complications, suggesting a large-scale randomized trial may not be practical while a prospective study is achievable.

Article Abstract

Background: The safety of waterbirth is contested because of the lack of evidence from randomized trials and conflicting results. This research assessed the feasibility of a prospective study of waterbirth (trial or cohort).

Methods: We conducted a prospective cohort study at an Australian maternity hospital. Eligible women with uncomplicated pregnancies at 36 weeks of gestation were recruited and surveyed about their willingness for randomization. The primary midwife assessed waterbirth eligibility and intention on admission in labor, and onset of second stage. Primary outcomes measured feasibility. Intention-to-treat analysis, and per-protocol analysis, compared clinical outcomes of women and their babies who intended waterbirth and nonwaterbirth at onset of second stage.

Results: 1260 participants were recruited; 15% (n = 188) agreed to randomization in a future trial. 550 women were analyzed by intention-to-treat analysis: 351 (waterbirth) and 199 (nonwaterbirth). In per-protocol analysis, 14% (n = 48) were excluded. Women in the waterbirth group were less likely to have amniotomy and more likely to have water immersion and physiological third stage. There were no differences in other measures of maternal morbidity. There were no significant differences between groups for serious neonatal morbidity; four cord avulsions occurred in the waterbirth group with none in the landbirth group. An RCT would need approximately 6000 women to be approached at onset of second stage.

Conclusions: A randomized trial of waterbirth compared with nonwaterbirth, powered to detect a difference in serious neonatal morbidity, is unlikely to be feasible. A powered prospective study with intention-to-treat analysis at onset of second stage is feasible.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790445PMC
http://dx.doi.org/10.1111/birt.12635DOI Listing

Publication Analysis

Top Keywords

onset second
16
intention-to-treat analysis
12
waterbirth
9
trial waterbirth
8
prospective study
8
second stage
8
per-protocol analysis
8
waterbirth group
8
serious neonatal
8
neonatal morbidity
8

Similar Publications

Objective: There is no evidence to suggest that an association exists between the remnant cholesterol (RC) to high-density lipoprotein cholesterol (HDL-C) ratio and gestational diabetes mellitus (GDM). In this study, the RC/HDL-C ratio during the first trimester was examined as a potential indicator of the onset of GDM during the second trimester.

Methods: This was a secondary analysis of data from a Korea-based prospective cohort study.

View Article and Find Full Text PDF

Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study.

Cancer Immunol Immunother

January 2025

Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.

The combined use of tocilizumab (TCZ) and immune checkpoint inhibitors (ICIs) in cancer treatment is gaining attention, but preclinical studies are lacking. Our study aims to investigate the synergistic anti-tumor effect of TCZ combined with ICIs and its role in treating immune-related adverse events (irAEs). The clinical significance of high interleukin-6 (IL-6) expression in tumor patients was analyzed from the Cancer Genome Atlas (TCGA) database.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

AviadoBio, London, London, United Kingdom.

Background: Frontotemporal dementia (FTD) presents with a change in personality, behaviour and language and is the second most common cause of young-onset dementia after Alzheimer's disease. Loss of function mutations in GRN, encoding progranulin (PGRN), causes FTD in the heterozygous state, accounting for 5-10% of all FTD cases. PGRN is essential for normal lysosomal function and neuronal survival.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

University of Missouri - St. Louis, Saint Louis, MO, USA.

Background: Haplotypes are patterns of nucleotides in close proximity along a chromosome that are passed together across time and space. These patterns dictate the specific properties of proteins produced and the regulation of this production. General haplotype inference methods phase all provided genotypes within the region of interest into two haplotypes without regard for the ages or evolutionary impact of each mutation, thus force the inclusion of more recent and/or neutral mutations.

View Article and Find Full Text PDF

Background: The sortilin-related receptor 1 protein, SORL1, interacts with retromer to regulate trafficking of cargo out of the early endosome. Genetic variants in SORL1 that lead to a premature protein truncation (PTVs) are observed almost exclusively in Alzheimer's disease (AD) patients, suggesting SORL1's haploinsufficiency may be causal for AD. However, the large majority of SORL1 variants are rare missense variants which affect diverse structural domains, some of which may be causative for disease or (strongly) risk-increasing, while others are (likely) benign.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!